ARCHIVES

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

NCI To Spend About $150 Mil. On Cancers That Affect Only Women

April 26, 1991

Judge Invalidates Bristol-Myers’ Claims For The Administration Of Taxol.

March 3, 2000

NCI To Offer Compromise On Including “Chop-Like Elements” In CCOP, Agrees Consortia “Appropriate”

May 14, 1982

Cooperative Groups, NCI To Talk About Overlaps

March 14, 1975

Funding Opportunities: ACS Calif. Division Calls for Applications

August 1, 1997

Letter to the Editors: Society of Toxicology Comments On President’s Cancer Panel Report

August 6, 2010